Associated Papers
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
Dey P et al.
Oncogene, 2026
Profiling of HER2, KRAS, and PIK3CA mutations in uterine cervical neuroendocrine carcinoma and implications for oncogenic driver targeting therapy.
Chao WR et al.
Cancer Genetics, 2025
Genetic landscapes of breast tumors by next-generation sequencing with focus on less common types and genotype-phenotype correlations.
Hoda RS et al.
Human Pathology, 2025
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
De A et al.
Research Square, 2025
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.
Waliany S et al.
Cancer Medicine, 2024
HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy.
Chao WR et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2024
ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China.
Li H et al.
Tumori, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF et al.
Jama Oncology, 2021
Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
Riedlinger GM et al.
Breast Cancer Research : Bcr, 2021
Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis.
Uchida S et al.
Pathology Oncology Research : Por, 2021
Phase and context shape the function of composite oncogenic mutations.
Gorelick AN et al.
Nature, 2020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Robichaux JP et al.
Cancer Cell, 2019
High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features.
Rosa-Rosa JM et al.
Cancers, 2019
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ et al.
European Urology, 2017
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F et al.
Breast Cancer Research and Treatment, 2017
ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z et al.
Oncotarget, 2016
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
Deniziaut G et al.
Oncotarget, 2016
Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH et al.
Oncotarget, 2015